Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Day 1

ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.

solaci
solaci
474
0

Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based on the proven clinical benefit of drugs such as ACEIs or ARBs in treating patients with renal failure, the study randomized 8700 treated with aliskiren or placebo, in a 32 month follow up scheme. No differences were observed in the composite cardio-renal end points, neither when CV and renal end points were observed individually.

Altitude-slides
Hans Henrik Parving
2012-08-25

Original title: ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints

Previous article
PURE: This study shows different patterns of cardiovascular risk factor prevalence in countries with different socio-economical background, and recommends individualized intervention..
Next article
PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .
solaci
solaci

More articles by this author

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

solaci - 0
 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25

DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.

solaci - 0
 DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.  Read articleJames K. Min2012-08-25

Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment

solaci - 0
Editorial Comment: Fifty per cent of all HF patients involves Diastolic Heart Failure or HF with conserved ventricular function. This study aimed at evaluating...

PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .

solaci - 0
Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25
solaci -
SOLACI Sessionsspot_img

Recent Articles

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Dr. Juan Manuel Pérez - 0
Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Left Atrial Appendage Closure: Implantation Depth Could Determine Thrombosis Risk

Dr. Andrés Rodríguez - 0
Left atrial appendage closure (LAAC) has undergone significant advances over the past two decades. This progress has been driven by the development of new...

Influence of cusp-overlap and three-cusp coplanar techniques on new-onset conduction disturbances after TAVI

Dr. Juan Manuel Pérez - 0
New-onset conduction disturbances remain one of the most frequent complications after transcatheter aortic valve implantation (TAVI), being associated with worse long-term clinical outcomes. Among...